Positron emission tomography/computed tomography (PET/CT) imaging targeting the prostate-specific membrane antigen (PSMA) plays an increasingly important role in the detection and staging of primary and recurrent prostate cancer (PCa) and has proven superior over conventional imaging methods [1, 2]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.